Related references
Note: Only part of the references are listed.Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade
Petar Jelinic et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
APR-246 reactivates mutant p53 by targeting cysteines 124 and 277
Qiang Zhang et al.
CELL DEATH & DISEASE (2018)
Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer
Takeshi Fukumoto et al.
CELL REPORTS (2018)
Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade
Petar Jelinic et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Genomic and Epigenomic Signatures in Ovarian Cancer Associated with Resensitization to Platinum Drugs
Fang Fang et al.
CANCER RESEARCH (2018)
A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer
Rebecca Kristeleit et al.
GYNECOLOGIC ONCOLOGY (2017)
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman et al.
LANCET (2017)
ARID1A-mutated ovarian cancers depend on HDAC6 activity
Benjamin G. Bitler et al.
NATURE CELL BIOLOGY (2017)
Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden
Meredith L. Stone et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Pathogenesis and heterogeneity of ovarian cancer
Paul T. Kroeger et al.
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY (2017)
Immunotherapy in ovarian cancer
Venkatesh Krishnan et al.
CURRENT PROBLEMS IN CANCER (2017)
Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine
Dmitriy Zamarin et al.
GYNECOLOGIC ONCOLOGY (2016)
Ovarian cancer and the immune system - The role of targeted therapies
Taylor B. Turner et al.
GYNECOLOGIC ONCOLOGY (2016)
Targeting the cancer epigenome for therapy
Peter A. Jones et al.
NATURE REVIEWS GENETICS (2016)
BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1
Zhenfeng Zhang et al.
THERANOSTICS (2016)
Tumor infiltrating lymphocytes in ovarian cancer
Phillip P. Santoiemma et al.
CANCER BIOLOGY & THERAPY (2015)
DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts
David Roulois et al.
CELL (2015)
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
Katherine B. Chiappinelli et al.
CELL (2015)
Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers
Benjamin G. Bitler et al.
NATURE MEDICINE (2015)
Epigenetic treatment of solid tumours: a review of clinical trials
Clara Nervi et al.
CLINICAL EPIGENETICS (2015)
Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model
Lei Wang et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Intermediate clinical endpoints: A bridge between progression-free survival and overall survival in ovarian cancer trials
Ursula A. Matulonis et al.
CANCER (2015)
The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
Nicolas J. Llosa et al.
CANCER DISCOVERY (2015)
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Patricia A. J. Muller et al.
CANCER CELL (2014)
p53 as a target for the treatment of cancer
Michael J. Duffy et al.
CANCER TREATMENT REVIEWS (2014)
Targeting Tumor Suppressor p53 for Cancer Therapy: Strategies, Challenges and Opportunities
Bo Hong et al.
CURRENT DRUG TARGETS (2014)
Catumaxomab for the Treatment of Malignant Ascites in Patients With Chemotherapy-Refractory Ovarian Cancer A Phase II Study
Jonathan S. Berek et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2014)
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
Eric Pujade-Lauraine et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
ZNF300P1 Encodes a lincRNA that regulates cell polarity and is epigenetically silenced in type II epithelial ovarian cancer
Brian Gloss et al.
MOLECULAR CANCER (2014)
The H3K9 methyltransferase G9a is a marker of aggressive ovarian cancer that promotes peritoneal metastasis
Kuo-Tai Hua et al.
MOLECULAR CANCER (2014)
A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors
Hatem H. Soliman et al.
ONCOTARGET (2014)
Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer
Kunle Odunsi et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Unravelling mechanisms of p53-mediated tumour suppression
Kathryn T. Bieging et al.
NATURE REVIEWS CANCER (2014)
Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K channel
Mine S. Cicek et al.
HUMAN MOLECULAR GENETICS (2013)
Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies
Gerald S. Falchook et al.
INVESTIGATIONAL NEW DRUGS (2013)
Chromatin H3K27me3/H3K4me3 histone marks define gene sets in high-grade serous ovarian cancer that distinguish malignant, tumour-sustaining and chemo-resistant ovarian tumour cells
N. Chapman-Rothe et al.
ONCOGENE (2013)
Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer
Hui Shen et al.
NATURE COMMUNICATIONS (2013)
Epigenetic Resensitization to Platinum in Ovarian Cancer
Daniela Matei et al.
CANCER RESEARCH (2012)
Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis
Wei-Ting Hwang et al.
GYNECOLOGIC ONCOLOGY (2012)
Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer
Kelly L. Bolton et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
MDM2 inhibition in liposarcoma: a step in the right direction
Anastasia Constantinidou et al.
LANCET ONCOLOGY (2012)
Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study
Isabelle Ray-Coquard et al.
LANCET ONCOLOGY (2012)
Correction: VENNTURE–A Novel Venn Diagram Investigational Tool for Multiple Pharmacological Dataset Analysis
Bronwen Martin et al.
PLoS One (2012)
Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)
Michael T. McCabe et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Recent Progress in the Diagnosis and Treatment of Ovarian Cancer
Danijela Jelovac et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Phase 1b-2a Study to Reverse Platinum Resistance Through Use of a Hypomethylating Agent, Azacitidine, in Patients With Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer
Siqing Fu et al.
CANCER (2011)
Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing
Tom Walsh et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non-Small Cell Lung Cancer
Rosalyn A. Juergens et al.
CANCER DISCOVERY (2011)
Researchers find a new cancer gene and a possible link between ovarian cancer and endometriosis
[Anonymous]
WOMENS HEALTH (2010)
ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
Kimberly C. Wiegand et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Systematic Review and Meta-analysis of Ovarian Cancers: Estimation of Microsatellite-High Frequency and Characterization of Mismatch Repair Deficient Tumor Histology
Tuya Pal et al.
CLINICAL CANCER RESEARCH (2008)
Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: A Gynecologic Oncology Group study
Angeles Alvarez Secord et al.
GYNECOLOGIC ONCOLOGY (2008)
Low-Grade Serous Ovarian Cancer: a Unique Disease
Kathleen M. Schmeler et al.
CURRENT ONCOLOGY REPORTS (2008)
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer
Junzo Hamanishi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Intraperitoneal cisplatin and paclitaxel in ovarian cancer
DK Armstrong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Promoter hypermethylation profile of ovarian epithelial neoplasms
PB Makarla et al.
CLINICAL CANCER RESEARCH (2005)
Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis -: A mutational analysis with immunohistochemical correlation
G Singer et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2005)
We of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage
K Yoshida et al.
CANCER SCIENCE (2004)
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer
L Zhang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Diverse tumorigenic pathways in ovarian serous carcinoma
G Singer et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
Share Paper
